Приказ основних података о документу

dc.creatorBeloica, Sofija
dc.creatorCvijić, Sandra
dc.creatorBogataj, Marija
dc.creatorParojčić, Jelena
dc.date.accessioned2019-09-02T11:48:39Z
dc.date.available2019-09-02T11:48:39Z
dc.date.issued2015
dc.identifier.issn0928-0987
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2464
dc.description.abstractWithin the last decades, physiologically based pharmacokinetic models have emerged into a biopharmaceutical toolkit that has been proven useful in understanding how physicochemical, formulation and physiological factors affect oral drug absorption. The purpose of this study was to develop a drug specific physiologically based pharmacokinetic model that will allow mechanistic interpretation of oral absorption from dosage forms exhibiting different in vitro and different in vivo performance (i.e. immediate release and sustained release tablets) and identification of bioperformance dissolution testing. Ibuprofen was chosen to be used for the "proof of concept" considering it is well characterised and the necessary physicochemical, biopharmaceutical and pharmacokinetic properties for model development could be found in the literature. Gastrointestinal simulation technology implemented in Simcyp (R) was successful in estimating ibuprofen oral absorption. The developed model exhibited good generalisation ability for the dosage forms studied. The obtained results indicate that the model was sensitive to input kinetics represented by the in vitro drug release profiles obtained under various dissolution conditions. According to the obtained results, reciprocating cylinder apparatus with biorepresentative change in media pH might be considered as bioperformance dissolution in the case of the two ibuprofen SR products studied. These results further justify the use of integrated in vitro-in vivo-in silico approach in estimating bioperformance of oral solid dosage forms.en
dc.publisherElsevier Science BV, Amsterdam
dc.relationinfo:eu-repo/grantAgreement/MESTD/Technological Development (TD or TR)/34007/RS//
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Pharmaceutical Sciences
dc.subjectBioperformance dissolutionen
dc.subjectGastrointestinal simulationen
dc.subjectIn vitro-in vivo-in silica approachen
dc.subjectIbuprofenen
dc.titleIn vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tabletsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЦвијић, Сандра; Паројчић, Јелена; Белоица, Софија; Богатај, Марија;
dc.citation.volume75
dc.citation.spage151
dc.citation.epage159
dc.citation.other75: 151-159
dc.citation.rankM21
dc.identifier.wos000356552500016
dc.identifier.doi10.1016/j.ejps.2015.03.027
dc.identifier.pmid25861718
dc.identifier.scopus2-s2.0-84929706296
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу